Medical Devices; Hematology and Pathology Devices; Classification of the Digital Cervical Cytology Slide Imaging System With Artificial Intelligence Algorithm
The Food and Drug Administration (FDA) is classifying the digital cervical cytology slide imaging system with artificial intelligence algorithm into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the digital cervical cytology slide imaging system with artificial intelligenc
Excerpt shown under fair-use limits. Full text remains with the original publisher.
People in this coverage
Explore their history and attributable record. Being mentioned does not imply endorsement.
Agency framingThe FDA frames the classification as a proactive safety measure, emphasizing assurance of safety and effectiveness.
Benefit emphasisThe statement highlights anticipated patient benefits and reduced regulatory burden, presenting the decision positively.
Context
AI analysis
Missing context
The announcement does not explain what specific special controls will apply, how the classification compares to prior regulatory status, the timeline for implementation, or any stakeholder responses.
Important context
Class II classification indicates the device is considered moderate risk and will be subject to special controls rather than the more stringent premarket approval process required for Class III devices.
Opinion vs. reporting
AI analysis
The text primarily reports an FDA regulatory action, but includes the agency’s evaluative language (e.g., "We believe this action will also enhance patients' access...") which reflects an internal perspective rather than neutral reporting.